Physician profile
Michael P Binder
NPI 1922198357
$2,078.83
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $172 · 2021: $244 · 2022: $592 · 2023: $519 · 2024: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,106.82 | 2019-2024 | Grafix Pl, Collagenase Santyl, Renasys Go V2 Home |
| Organogenesis INC. | $460.23 | 2019-2024 | Puraply |
| Convatec INC. | $129.41 | 2019-2023 | |
| Melinta Therapeutics, LLC | $106.85 | 2019-2023 | Kimyrsa |
| Kerecis Limited | $87.06 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Abbvie INC. | $38.12 | 2022 | |
| Ethicon US, LLC | $26.87 | 2019 | |
| Integra Lifesciences Corporation | $24.44 | 2022 | |
| Next Science LLC | $21.92 | 2024 | Surgx, Xperience, Blastx |
| Cashflow Solutions, LLC | $17.57 | 2023 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Kci USA, INC. | $15.75 | 2023 | V.A.C. Dermatac, Kerramax Care, Activ.A.C. |
| Tetraphase Pharmaceuticals, INC. | $15.27 | 2019 | |
| Merck Sharp & Dohme LLC | $14.52 | 2021 | |
| Adma Biomanufacturing LLC | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Binder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.